Hematologic Oncology Update cover art

All Episodes

Hematologic Oncology Update — 141 episodes

#
Title
1

Multiple Myeloma — Fifth Annual National General Medical Oncology Summit

2

Chronic Lymphocytic Leukemia — Fifth Annual National General Medical Oncology Summit

3

Diffuse Large B-Cell Lymphoma and Follicular Lymphoma — Fifth Annual National General Medical Oncology Summit

4

Bruton Tyrosine Kinase Inhibitors for Chronic Lymphocytic Leukemia — Year in Review Series on Relevant New Datasets and Advances

5

CELMoDs for Multiple Myeloma — Microlearning Activity 2 with Dr Paul G Richardson

6

Immune Thrombocytopenia — Microlearning Activity 4 with Dr Hanny Al-Samkari: ASH 2025 Review

7

CELMoDs for Multiple Myeloma — Microlearning Activity 1 with Dr Paul G Richardson

8

Immune Thrombocytopenia — Microlearning Activity 3 with Dr Hanny Al-Samkari: ASH 2025 Review

9

CD19 x CD3 BiTEs for Acute Lymphoblastic Leukemia — An Interview with Dr Bijal Shah

10

Chronic Lymphocytic Leukemia — An Interview with Prof Constantine Tam on Key Presentations from the 2025 ASH Annual Meeting

11

Immune Thrombocytopenia — Microlearning Activity 2 with Dr Hanny Al-Samkari: ASH 2025 Review

12

Immune Thrombocytopenia — Microlearning Activity 1 with Dr Hanny Al-Samkari: ASH 2025 Review

13

Multiple Myeloma: Inside the Issue of Cereblon E3 Ligase Modulators

14

Relapsed/Refractory Multiple Myeloma — Microlearning Activity 2 with Dr Sagar Lonial: ASH 2025 Review

15

Immune Thrombocytopenia — ASH 2025 Review

16

Relapsed/Refractory Multiple Myeloma — Microlearning Activity 1 with Dr Sagar Lonial: ASH 2025 Review

17

Bispecific Antibodies in the Management of Lymphoma — ASH 2025 Review

18

Relapsed/Refractory Multiple Myeloma — ASH 2025 Review

19

Follicular Lymphoma and Diffuse Large B-Cell Lymphoma — Proceedings from a Symposium Series Preceding the 67th ASH Annual Meeting and Exposition

20

Myelofibrosis and Systemic Mastocytosis — Proceedings from a Symposium Series Preceding the 67th ASH Annual Meeting and Exposition

21

Chronic Lymphocytic Leukemia — Proceedings from a Symposium Series Preceding the 67th ASH Annual Meeting and Exposition

22

Acute Myeloid Leukemia — Proceedings from a Symposium Series Preceding the 67th ASH Annual Meeting and Exposition

23

Chronic Lymphocytic Leukemia — Proceedings from a Symposium Held in Partnership with the American Oncology Network

24

CAR T-Cell Therapy for Non-Hodgkin Lymphoma | Cancer Q&A — Discussing Common Questions Posed by Patients

25

Toxicities Associated with CAR T-Cell Therapy — An Interview with Dr Matthew Lunning

26

Patient Education Resource: Non-Hodgkin Lymphoma — Clinical Experts Address Common Questions Posed by Patients About CAR T-Cell Therapy

27

Diffuse Large B-Cell Lymphoma and Follicular Lymphoma — Proceedings from a Multitumor Symposium in Partnership with Florida Cancer Specialists & Research Institute

28

Acute Myeloid Leukemia — An Interview with Dr Eunice S Wang to Review Key Presentations from ASCO and EHA

29

Non-Hodgkin Lymphoma — The Implications of Recent Datasets for Current and Future Disease Management

30

Follicular Lymphoma — Proceedings from a Session Held During the Society of Hematologic Oncology 2025 Annual Meeting

31

Acute Myeloid Leukemia — An Interview with Dr Ghayas Issa on the Role of Menin Inhibitors

32

Relapsed/Refractory Multiple Myeloma — Proceedings from a Session Held During the Society of Hematologic Oncology 2025 Annual Meeting

33

Oncology Nursing Update: Multiple Myeloma — An Interview with Dr Beth Faiman on CAR T-Cell Therapy

34

Ocular Toxicities Associated with Antibody-Drug Conjugates and Other Cancer Therapies: Part 2 — An Interview with Dr Neel Pasricha on Adverse Event Management

35

Ocular Toxicities Associated with Antibody-Drug Conjugates and Other Cancer Therapies: Part 1 — Inside the Issue of Adverse Event Management

36

Oncology Nursing Update: Newly Diagnosed Multiple Myeloma — An Interview with Ms Charise Gleason

37

Oncology Nursing Update: Newly Diagnosed Multiple Myeloma — An Interview with Prof Xavier Leleu

38

Relapsed/Refractory Multiple Myeloma — Oncology Q&A: Discussing Common Questions Posed by Patients

39

Multiple Myeloma | Oncology Q&A — Patient Education Resource: Clinical Experts Address Common Questions Posed by Patients with Relapsed/Refractory Multiple Myeloma

40

Acute Myeloid Leukemia — An Interview with Dr Jorge Cortes on Optimal Management of FLT3 and IDH1/2 Mutations

41

Multiple Myeloma — Optimizing the Selection of First-Line Therapy

42

Chronic Lymphocytic Leukemia — Proceedings from a Session Held During the 2025 ASCO Annual Meeting

43

Multiple Myeloma — Proceedings from a Webinar Held in Conjunction with the 2025 ASCO Annual Meeting

44

For Oncology Nurses: Chronic Lymphocytic Leukemia — Proceedings from the 2025 Annual ONS Congress

45

Non-Hodgkin Lymphoma — Proceedings from a Session Held During the 2025 ASCO Annual Meeting

46

For Oncology Nurses: Non-Hodgkin Lymphoma — Proceedings from the 2025 Annual ONS Congress

47

For Oncology Nurses: Chronic Myeloid Leukemia — Proceedings from the 2025 Annual ONS Congress

48

IDH-Mutant Low-Grade Glioma — An Interview with Dr Patrick Y Wen on Current and Future Management Strategies

49

Multiple Myeloma — Year in Review Series on Relevant New Datasets and Advances

50

Myelofibrosis — Year in Review Series on Relevant New Datasets and Advances

51

Non-Hodgkin Lymphoma — Year in Review Series on Relevant New Datasets and Advances

52

Systemic Mastocytosis and Myelofibrosis — Fourth Annual National General Medical Oncology Summit

53

Multiple Myeloma — Fourth Annual National General Medical Oncology Summit

54

Multiple Myeloma — An Interview with Dr Rafael Fonseca on Key Presentations from the 66th American Society of Hematology (ASH) Annual Meeting

55

Chronic Lymphocytic Leukemia — An Interview with Dr Lindsey Roeker on Key Presentations from the 66th American Society of Hematology (ASH) Annual Meeting

56

Relapsed/Refractory Follicular Lymphoma Part 3 — A Roundtable Discussion on the Selection and Sequencing of Other Novel Therapies

57

Non-Hodgkin Lymphoma — An Interview with Dr Jennifer Crombie on the Use of Bispecific Antibodies

58

Relapsed/Refractory Follicular Lymphoma Part 2 — A Roundtable Discussion on the Selection and Sequencing of CAR T-Cell Therapy

59

Non-Hodgkin Lymphoma — Fourth Annual National General Medical Oncology Summit

60

Non-Hodgkin Lymphoma — An Interview with Dr John P Leonard on Key Presentations from the 66th American Society of Hematology (ASH) Annual Meeting

61

Chronic Lymphocytic Leukemia — Year in Review Series on Relevant New Datasets and Advances

62

Immune Thrombocytopenia — A Roundtable Discussion on Current and Future Management Strategies

63

Relapsed/Refractory Follicular Lymphoma Part 1 — A Roundtable Discussion on the Selection and Sequencing of Bispecific Antibodies

64

Oncology Nursing Update Special 2-Part Edition: Bispecific Antibodies in Lymphoma — Part 2

65

Myelofibrosis — An Interview with Dr Raajit K Rampal on Key Presentations from the 66th American Society of Hematology (ASH) Annual Meeting

66

Chronic Lymphocytic Leukemia — Fourth Annual National General Medical Oncology Summit

67

Chronic Lymphocytic Leukemia — An Interview with Dr Catherine C Coombs on Real-World Cases and Current Questions and Controversies Presented at Recent Conferences

68

For Oncology Nurses: Bispecific Antibodies in Multiple Myeloma — An Interview with Dr Tiffany A Richards

69

Oncology Nursing Update Special 2-Part Edition: Bispecific Antibodies in Lymphoma — Part 1

70

Relapsed/Refractory Diffuse Large B-Cell Lymphoma — A Roundtable Discussion on Current and Future Management Strategies

71

Multiple Myeloma — An Interview with Dr Surbhi Sidana on Optimizing the Role of CAR T-Cell Therapy

72

Multiple Myeloma — Optimizing the Selection of First-Line Therapy with Dr Saad Zafar Usmani

73

Chronic Lymphocytic Leukemia with Dr Jennifer Woyach: Part 3 of a 3-Part Meet The Professor Series

74

Data + Perspectives: Clinical Investigators Discuss the Role of CAR T-Cell Therapy for Patients with Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

75

CAR T-Cell and Bispecific Therapy for Lymphoma — Part 3 of Our 6-Part ASH 2024 Friday Satellite Symposia Series

76

Myelofibrosis — Part 4 of Our 6-Part ASH 2024 Friday Satellite Symposia Series

77

Chronic Myeloid Leukemia — Part 1 of Our 6-Part ASH 2024 Friday Satellite Symposia Series

78

Acute Myeloid Leukemia — Part 5 of Our 6-Part ASH 2024 Friday Satellite Symposia Series

79

Multiple Myeloma — Part 6 of Our 6-Part ASH 2024 Friday Satellite Symposia Series

80

Chronic Lymphocytic Leukemia — Part 2 of Our 6-Part ASH 2024 Friday Satellite Symposia Series

81

Cases from the Community: Integrating New Research Findings into Current Practice — Myelofibrosis

82

Cases from the Community: Integrating New Research Findings into Current Practice — Leukemia and Myelodysplastic Syndromes

83

Practical Perspectives: Investigators Discuss the Current Management of Paroxysmal Nocturnal Hemoglobinuria

84

Data + Perspectives: Clinical Investigators Explore the Application of Recent Datasets in Current Oncology Care  — Multiple Myeloma

85

Meet The Professor: Optimizing the Management of Chronic Lymphocytic Leukemia — Part 2 of a 3-Part Series

86

Data + Perspectives: Clinical Investigators Explore the Application of Recent Datasets in Current Oncology Care  — Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

87

What Clinicians Want to Know About the Current and Future Role of EZH1/2 Inhibitors in the Care of Patients with Lymphoma

88

Practical Perspectives: Optimizing the Role of BTK Inhibitors in the Management of Mantle Cell Lymphoma

89

Practical Perspectives: Current Management of Chronic Myeloid Leukemia

90

Oncology Today with Dr Neil Love: Peripheral T-Cell Lymphoma

91

Meet The Professor: Optimizing the Management of Chronic Lymphocytic Leukemia — Part 1 of a 3-Part Series

92

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Multiple Myeloma

93

RTP Live from Chicago: Investigator Perspectives on the Role of Bispecific Antibodies in the Management of Lymphoma

94

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Myelofibrosis

95

Oncology Today with Dr Neil Love: Key Presentations on Lymphoma from Recent Major Conferences

96

Oncology Today with Dr Neil Love: Recent Advances in the Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

97

Oncology Today with Dr Neil Love: Bispecific Antibodies in the Management of Multiple Myeloma

98

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Acute Myeloid Leukemia

99

Meet The Professor: Optimizing the Management of Myelofibrosis — Part 2 of a 2-Part Series

100

Striving for Consensus: Current and Future Management of Paroxysmal Nocturnal Hemoglobinuria

101

Oncology Today with Dr Neil Love: Key Presentations on Myeloproliferative Neoplasms from Recent Major Conferences

102

Oncology Today with Dr Neil Love: Key Presentations on Chronic Lymphocytic Leukemia from Recent Major Conferences

103

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Lymphoma

104

Meet The Professor: Optimizing the Management of Myelofibrosis — Part 1 of a 2-Part Series

105

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Chronic Lymphocytic Leukemia

106

Meet The Professor: Optimizing the Management of Acute Myeloid Leukemia and Myelodysplastic Syndromes — Part 3 of a 3-Part Series

107

Meet The Professor: Optimizing the Management of Acute Myeloid Leukemia and Myelodysplastic Syndromes — Part 2 of a 3-Part Series

108

Meet The Professor: Optimizing the Management of Acute Myeloid Leukemia and Myelodysplastic Syndromes — Part 1 of a 3-Part Series

109

What Clinicians Want to Know About the Management of Relapsed/Refractory Mantle Cell Lymphoma

110

Oncology Today with Dr Neil Love: Key Presentations on Multiple Myeloma from Recent Major Oncology/Hematology Conferences

111

Oncology Today with Dr Neil Love: Bispecific Antibodies in the Management of Non-Hodgkin Lymphoma with Dr Matthew Matasar

112

What Clinicians Want to Know About Anti-CD38 Antibodies in the Management of Multiple Myeloma

113

Oncology Today with Dr Neil Love: Blastic Plasmacytoid Dendritic Cell Neoplasm

114

Oncology Today with Dr Neil Love: Emerging Role of CELMoDs (Cereblon E3 Ligase Modulators) and Other Novel Approaches to Targeting Protein Degradation Pathways in Multiple Myeloma

115

What Clinicians Want to Know About Toxicity Considerations Associated with BTK Inhibitors

116

Inside the Issue: The Current and Future Role of CD20 x CD3 Bispecific Antibodies in the Management of Non-Hodgkin Lymphoma

117

Oncology Today with Dr Neil Love: Role of BTK Inhibitors in Patients with Mantle Cell Lymphoma

118

Meet The Professor: Optimizing the Management of Soft Tissue Sarcoma and Related Connective Tissue Disorders — Part 2 of a 2-Part Series

119

Oncology Today with Dr Neil Love: Special Edition — Key Presentations on Chronic Lymphocytic Leukemia and Lymphoma from Recent Major Oncology/Hematology Conferences

120

Inside the Issue: Integrating Bispecific Antibodies into the Management of Multiple Myeloma — Patient Selection and Toxicity Management

121

Oncology Today with Dr Neil Love: Special Edition — What I Tell My Patients About New Treatments and Clinical Trials in Chronic Lymphocytic Leukemia

122

Inside the Issue: Novel Agents, Approaches and Strategies in the Management of Higher-Risk Myelodysplastic Syndromes

123

Oncology Today with Dr Neil Love: Immune Thrombocytopenia Edition

124

Oncology Today with Dr Neil Love: Management of Paroxysmal Nocturnal Hemoglobinuria

125

Meet The Professor: The Current and Future Management of Non-Hodgkin Lymphoma

126

Meet The Professor: Optimizing the Management of Soft Tissue Sarcoma and Related Connective Tissue Disorders — Part 1 of a 2-Part Series

127

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Acute Myeloid Leukemia and Myelodysplastic Syndromes

128

Oncology Today with Dr Neil Love: Key Presentations from the 64th American Society of Hematology (ASH) Annual Meeting: Multiple Myeloma Edition

129

Oncology Today with Dr Neil Love — Key Presentations from the 64th American Society of Hematology (ASH) Annual Meeting: Chronic Lymphocytic Leukemia Edition

130

Recent Advances and Future Directions in Chronic Lymphocytic Leukemia and Lymphomas — With Dr Danielle Brander and Craig Moskowitz (Proceedings from a Symposium in Partnership with NCOA and SCOS)

131

Oncology Today with Dr Neil Love: Key Presentations in Hodgkin and Non-Hodgkin Lymphomas from the 2022 ASH Annual Meeting

132

Inside the Issue — Optimizing the Management of Adverse Events Associated with BTK Inhibitors

133

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Hodgkin and Non-Hodgkin Lymphomas

134

Meet The Professor: Optimizing the Management of Multiple Myeloma — Part 4 of a 4-Part Series

135

Oncology Today with Dr Neil Love: Key Presentations on Myeloproliferative Neoplasms from the 2022 ASH Annual Meeting

136

Oncology Today with Dr Neil Love: Advances in Diffuse Large B-Cell Lymphoma

137

Oncology Today with Dr Neil Love: Key Presentations in Acute Myeloid Leukemia and Myelodysplastic Syndromes from the 2022 ASH Annual Meeting

138

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Multiple Myeloma

139

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Chronic Lymphocytic Leukemia

140

Meet The Professor: Optimizing the Management of Multiple Myeloma — Part 3 of a 4-Part Series

141

What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Acute Myeloid Leukemia